A pregnant woman, illuminated by soft sunlight, gently cradles her belly while surrounded by a tranquil Nordic landscape. In the background, a subtle depiction of healthcare professionals and vaccination imagery emphasizes safety. The scene captures serenity and protection, reflecting the safety of COVID-19 vaccines in early pregnancy.
COVID-19 has posed unique challenges for pregnant women, especially concerning the potential risks to the developing fetus. The latest research, a prospective Nordic registry-based study, has brought valuable insights into the risks of congenital anomalies in infants born to mothers who either contracted COVID-19 or were vaccinated against it during the first trimester.
According to the study, which examined 343,066 live births across Sweden, Denmark, and Norway, the researchers aimed to understand whether COVID-19 infection or vaccination during early pregnancy could increase the risk of congenital anomalies. The infants were assessed for anomalies using the well-established EUROCAT classification, which identifies a wide range of congenital defects.
No Significant Risks Found
Maria C. Magnus, the lead researcher, emphasized that the study found “no statistically significant association between COVID-19 infection or vaccination during the first trimester and an increased risk of major congenital anomalies.” The adjusted odds ratios indicated minimal variation, ranging from 0.84 to 1.69 across various categories of congenital anomalies, including eye anomalies, nervous system anomalies, and abdominal wall defects.
Jonas Söderling, one of the study’s co-authors, added that “the findings are reassuring for pregnant women and healthcare providers alike, especially given the urgency of vaccinations during the pandemic.” With more than 17,704 cases of infants showing congenital anomalies in this study, the researchers had substantial data to ensure robust conclusions.
Importance of Vaccine Safety Data
While vaccination during pregnancy has been widely recommended, the safety of vaccines in this context had not been fully evaluated prior to their widespread use. The study acknowledges the scarcity of randomized controlled trials involving pregnant women before vaccine authorization. “It’s crucial that pregnant women are included in such research in the future to provide more conclusive data,” stated Anne K. Örtqvist, co-author of the study.
Despite these limitations, observational studies after the introduction of vaccines have consistently shown no increased risk of major pregnancy complications. “Pregnant women should be confident in the safety of COVID-19 vaccines, as this study further supports the absence of harmful effects during the early stages of pregnancy,” affirmed Anne-Marie Nybo Andersen, another key contributor.
Conclusions and Implications
The study’s results bring peace of mind to pregnant women and their care teams, supporting the safety of COVID-19 vaccination in early pregnancy. Furthermore, it indicates that even those who contracted COVID-19 in the first trimester are not at higher risk of delivering infants with major congenital anomalies.
As healthcare policies evolve, it is essential for governments to rely on such large-scale, evidence-based studies to guide vaccination recommendations and protocols. “Data from Sweden, Denmark, and Norway offer a rare glimpse into large-scale population outcomes,” said Olof Stephansson, who worked extensively on analyzing the dataset.
Siri E. Håberg emphasized the significance of the findings for future research: “Long-term monitoring of maternal and infant health will continue to be a priority, especially as new variants of COVID-19 emerge.”
Citation:
Magnus MC, Söderling J, Örtqvist AK, Andersen AMN, Stephansson O, Håberg SE, Urhoj SK. Covid-19 infection and vaccination during first trimester and risk of congenital anomalies: Nordic registry based study. BMJ. 2024;386.
License:
This content is generated from the original article original article and it’s under Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
